刘如,袁晋青

• 1:北京协和医学院中国医学科学院国家心血管病中心阜外心血管病医院心血管内科

摘要(Abstract)：

<正>冠状动脉介入技术应用于临床的30年间,人们一直坚信这一血运重建方法可使大多数缺血性心脏病患者获益。随着近十年来冠状动脉旁路移植术(coronary artery bypass graft,CABG)和经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的长足发展,例如不停跳搭桥、微创搭桥、全动脉化搭桥、更佳围术期护理、支架结构设计的改

关键词(KeyWords)： 稳定性冠心病;血运重建策略;经皮冠状动脉介入治疗;冠状动脉旁路移植术;SYNTAX积分

Abstract:

Keywords:

基金项目(Foundation): 国家“十二五”科技支撑计划项目(2011BAI11B07)

作者(Author): 刘如,袁晋青

参考文献(References)：

• [1]刘兆平.2013ESC稳定性冠状动脉疾病管理指南重点解读.中国医学前沿杂志(电子版),2013,5:48-50.
• [2]Montalescot G,Sechtem U,Achenbach S,et al.2013 ESC guidelines on themanagementof stable coronary artery disease:The Task Force on the management of stable coronary artery disease of the European Society of Cardiology.Eur Heart J,2013,34:2949-3003.
• [3]Fox K,Garcia MA,Ardissino D,et al.Guidelines on the management of stable angina pectoris:executive summary.The Task Force on the management of stable angina pectoris of the European Society of Cardiology.Eur Heart J,2006,27:1341-1381.
• [4]Boden WE,O'Rourke RA,Teo KK,et al.Optimal Medical Therapy with or without PCI for Stable Coronary Disease.N Engl J Med,2007,356:1503-1516.
• [5]Weintraub WS,Spertus JA,Kolm P,et al.Effect of PCI on quality of life in patients with stable coronary disease.N Engl J Med,2008,359:677-687.
• [6]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.J Am Coll Cardiol,2011,58:e44-e122.
• [7]Holmes DR Jr,Leon MB,Moses JW,et al.Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis.Circulation,2004,109:634-640.
• [8]Hodgson JM,Stone GW,Lincoff AM,et al.Late Stent Thrombosis:Considerations and Practical.Advice for the Use of Drug-Eluting Stents:A Report From the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force.Catheter Cardiovasc Interv,2007,69:327-333.
• [9]Stettler C,Wandel S,Allemann S,et al.Outcomes associated with drug-eluting and bare-metal stents:a collaborative network meta-analysis.Lancet,2007,370:937-948.
• [10]Eisenstein EL,Wijns W,Fajadet J,et al.Long-term clinical and eeonomie analysis of the endeavor drug-eluting stent versus the driver bare-metal Stent:4-year resuhs from the ENDEAVORⅡTrial(Randomized controlled trial to evaluate the safety and efficacy of the medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).J ACCCardiovasc Interv,2009,2:1l78-1187.
• [11]Leon MB,Kandzari DE,Eisenstein EL,et al.Late safety,efficacy,and cost-efectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions:2-year follow-up from the ENDEAVOR IV trial(Randomized,Controlled Trial of the Medtronic Endeavor Drug[ABT-578]Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).JACC Cardiovasc Interv,2009,2:1208-1218.
• [12]Lotan C,Meredith IT,Mauri L,et al.Rothman for the E-Five Investigators.Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice:12-Month Data From the E-Five Registry.JACC Cardiovsc Interv,2009,2:1227-1235.
• [13]Sheiban I,Villata G,Bollat I M,et al.Next-generation drug-eluting stents in coronary artery disease:focus on everolimus-eluting stent.Vasc Health Risk Manag,2008,4:31-38.
• [14]Palmerini T,Biondi-Zoccai G,Della Riva D,et al.Stent thrombosis with drug-eluting and bare-metal stents:evidence from a comprehensive network meta-analysis.Lancet,2012,379:1393-1402.
• [15]Windecker S,Stortecky S,Stefanini GG,et al.Revascularization versus medical treatment in patients with stable coronary artery disease:network meta-analysis.BMJ,2014,348:g3859.
• [16]Yusuf S,Zucker D,Peduzzi P,et al.Effect of coronary artery bypass graft surgery on survival:overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.Lancet,1994,344:563-750.
• [17]Mohr FW,Morice MC,Kappetein AP,et al.Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease:5-year follow-up of the randomized,clinical SYNTAX trial.Lancet,2013,381:629-638.
• [18]Windecker S,Kolh P,Alfonso F,et.al.2014 ESC/EACTS Guidelines on myocardial revascularization.Kardiol Pol,2014,72:1253-1379.
• [19]BARI Investigators.Seven-year outcome in the Bypass Angioplasty Revascularization Investigation(BARI)by treatment and diabetic Status.J Am Coil Cardiol,2000,35:1122-1129.
• [20]Frye RL,August P,Brooks MM,et al.A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease.N Engl J Med,2009,360:2503-2515.
• [21]Kapur A,Hall RJ,Malik IS,et al.Randomized comparison of percutaneous coronary intervention with coronary bypass grafting in diabetic patients.1-year results of the CARDia(coronary artery revascularization in diabetes)trial.J Am Coll Cardiol,2010,55:432-440.
• [22]Farkouh ME,Domanski M,Sleeper LA,et al.Strategies for Multivessel Revascularization in Patients with Diabetes.N Engl J Med,2012,367:2375-2384.
• [23]Bech GJ,De Bruyne B,Pijls NH,et al.Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis.a randomized trial.Circulation,2001,103:2928-2934.
• [24]Pijls NH,Fearon WF,Tonino PA,et al.Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease:2-year followup of the FAME(Fractional Flow Reserve Versus Angiography for Multivessel Evaluation)study.J Am Coll Cardiol,2010,56:177-184.
• [25]De Bruyne B,Pijls NHJ,Kalesan B,et al.Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.N Engl J Med,2012,367:991-1001.
• [26]De Bruyne B,Fearon WF,Pijls NH,et al.Fractional flow reserve-guided PCI for stable coronary artery disease.N Engl J Med,2014,371:1208-1217.
• [27]Sechtem U.Is FAME 2 a breakthrough for PCI in stable coronary disease?Clin Res Cardiol,2014.[Epub ahead of print]